A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis
A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis
复制标题
DOI：
10.1016/j.jns.2005.05.011
复制
发表时间：
2005-10-15
影响因子：
4.4
通讯作者：
Osame, M
中科院分区：
文献类型：
--
作者：
Matsuzaki, T;Saito, M;Osame, M
10例人类T细胞嗜淋巴细胞病毒1型（HTLV-1）相关性脊髓病/热带痉挛性轻瘫（HAM/TSP）患者在一项非对照的初步试验中，口服含发酵乳的活干酪乳杆菌菌株Shirota（LcS）进行治疗。4周后评估HTLV-1前病毒载量、运动功能、神经学发现和免疫学参数。虽然LcS并没有改变外周血单个核细胞的所有检查的细胞表面表型的频率或绝对数，但口服US制剂4周后，NK细胞活性显著增加。US治疗后还观察到痉挛状态（改良Ashworth量表评分）和泌尿系统症状改善。整个研究期间，所有10名患者均未观察到不良反应。我们的研究结果表明，US可能是一种安全和有益的药物治疗HAM/TSP，因此，随机对照研究是必要的。(c)2005 Elsevier B. V.保留所有权利。
Ten patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) were treated in an uncontrolled preliminary trial by oral administration of viable Lactobacillus casei strain Shirota (LcS) containing fermented milk. HTLV-1 provirus load, motor function, neurological findings, and immunological parameters were evaluated after 4 weeks. Although LcS did not change the frequencies or absolute numbers of all the examined cell surface phenotypes of peripheral blood mononuclear cells, NK cell activity was significantly increased after 4 weeks of oral administration of US preparation. Improvements in spasticity (modified Ashworth Scale scores) and urinary symptoms were also seen after US treatment. No adverse effect was observed in all the 10 patients throughout the study period. Our results indicated that US may be a safe and beneficial agent for the treatment of HAM/TSP; therefore randomized controlled studies are warranted. (c) 2005 Elsevier B.V. All rights reserved.